Inhaled corticosteroids in COPD
49 results
1 - 49
Inhaled corticosteroids increase pneumonia risk in stable COPD- Risk of serious pneumonia in COPD patients using inhaled corticosteroids
- Corticosteroids benefit patients with moderate to severe COPD
- Steroid inhalers increase fracture risk in COPD
- Inhaled steroids for COPD associated with increased risk of pneumonia
- Inhaled steroids only decrease COPD exacerbations slightly
- Triple inhaled therapy for COPD effective for selected patients
- Inhaled budesonide for COPD not associated with pneumonia
- Low-dose theophylline is minimally helpful, if at all, in preventing COPD exacerbations
- Antibiotic and corticosteroid treatment effective for acute exacerbations of COPD
- Salmeterol + fluticasone better than tiotropium in COPD (INSPIRE)
- LABA+LAMA+ICS associated with greater decline in all-cause mortality than LABA+LAMA in patients with severe COPD (IMPACT)
- USPSTF 2022: Recommendation against screening for chronic obstructive pulmonary disease (D recommendation)
- Tiotropium via Soft Mist Inhaler increases all-cause mortality in COPD
- Triple inhaled therapy provides a small reduction in moderate exacerbations, no effect on severe exacerbations (ETHOS)
- Guidelines for the management of COPD
- Mepolizumab provides only a small reduction in moderate exacerbations when added to triple inhaler therapy for eosinophilic COPD (MATINEE)
- Guidelines for COPD (ACP)
- Population-based case-finding intervention to identify undiagnosed COPD and asthma has minimal benefits
- Canadian Thoracic Society guidelines for pharmacotherapy of stable chronic obstructive pulmonary disease